Literature DB >> 2930722

Burkitt cell acute leukaemia (L3 ALL) in adults: a report of 18 cases.

P Fenaux1, J L Lai, O Miaux, M Zandecki, J P Jouet, F Bauters.   

Abstract

Between 1981 and 1987, L3 ALL was diagnosed in 18 adult patients, with a median age of 26 (range 16-66) and M/F ratio of 3.5. At diagnosis, 11 patients had splenomegaly, 11 had enlarged lymph nodes, and 15 patients had central nervous system (CNS) disease, of whom 10 had mental neuropathy. Anaemia was found in 13 patients, thrombocytopenia in 17 and the median white cell count was 25.5 x 10(9)/I (range 8.6-89). Surface immunoglobulins were found on the blasts of every patient. Seventeen patients had a t(8;14) (q24;q32) translocation. One had an apparently normal karyotype, but only six mitoses could be examined. During the period of the study different treatment protocols, which comprised increasingly intensive systemic and CNS chemotherapy, were used. Six patients died less than 3 weeks after admission, two of them of acute tumour lysis syndrome and two of CNS haemorrhage. In two other patients, rapid progression of CNS leukaemia was seen in spite of the treatment. Ten patients (56%) achieved complete remission (CR). Two were allografted and two were autografted early in CR. Four patients relapsed, three of the four relapses involving the CNS. A median actuarial disease-free survival was not attained, and a plateau was achieved at 57% after 7 months, with no later relapse. Median actuarial survival of the 18 patients was only 6 months, but a plateau was obtained at 31% after 11 months. Prognosis seemed related to the intensity of chemotherapy: recent patients, treated more aggressively, achieved CR more often than earlier patients, treated with less intensive protocols, although the number of patients was too small to draw any firm conclusion. The initial white cell count was also a prognostic factor, as none of the patients with more than 30 x 10(9)/I leucocytes achieved CR. Our results suggest that the outcome of adult L3 ALL can be improved, as in children, by increased intensity of treatment, particularly with regard to CNS leukaemia therapy. Early deaths are still frequent, however, but their incidence can probably be reduced by better prevention and early management of the acute tumour lysis syndrome.

Entities:  

Mesh:

Year:  1989        PMID: 2930722     DOI: 10.1111/j.1365-2141.1989.tb04294.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

1.  Acute lymphoblastic leukaemia of the L3 subtype in adults in the Northern health region of England 1983-99.

Authors:  M R Velangi; M M Reid; N Bown; G H Jackson; G P Summerfield; S J Proctor; P R A Taylor
Journal:  J Clin Pathol       Date:  2002-08       Impact factor: 3.411

2.  The BFM-protocol for HIV-negative Burkitt's lymphomas and L3 ALL in adult patients: a high chance for cure.

Authors:  H W Pees; H Radtke; J Schwamborn; N Graf
Journal:  Ann Hematol       Date:  1992-11       Impact factor: 3.673

Review 3.  Biology and treatment of adult acute lymphoblastic leukemia.

Authors:  L Levitt; R Lin
Journal:  West J Med       Date:  1996-02

4.  Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens.

Authors:  Jennifer L Kelly; Stephen R Toothaker; Lauren Ciminello; Dieter Hoelzer; Harald Holte; Ann S LaCasce; Graham Mead; Deborah Thomas; Gustaaf W Van Imhoff; Brad S Kahl; Bruce D Cheson; Ian T Magrath; Richard I Fisher; Jonathan W Friedberg
Journal:  Clin Lymphoma Myeloma       Date:  2009-08

5.  Spinal cord compression in an adolescent with relapsed B-precursor acute lymphoblastic leukemia and mental neuropathy.

Authors:  Elpis Mantadakis; Aspasia Katragkou; Eufrosini Papadaki; Stefanos Papadhimitriou; George Paterakis; Eftichia Stiakaki; Maria Kalmanti
Journal:  Int J Hematol       Date:  2008-09-18       Impact factor: 2.490

Review 6.  Treatment of adolescents with aggressive B-cell malignancies: the pediatric experience.

Authors:  Jonas Lange; Birgit Burkhardt
Journal:  Curr Hematol Malig Rep       Date:  2013-09       Impact factor: 3.952

7.  Prolonged disease-free survival in an adult presenting with Burkitt-type acute lymphoblastic leukaemia and CNS disease.

Authors:  K Imrie; M A Baker; H A Messner; A Keating
Journal:  J R Soc Med       Date:  1992-01       Impact factor: 18.000

Review 8.  Burkitt lymphoma in adolescents and young adults: management challenges.

Authors:  Massimo Dozzo; Francesca Carobolante; Pietro Maria Donisi; Annamaria Scattolin; Elena Maino; Rosaria Sancetta; Piera Viero; Renato Bassan
Journal:  Adolesc Health Med Ther       Date:  2016-12-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.